CORT Alert: FDA Rejection Sparks Class Action Concerns!

Overview – FDA Rejection and Class Action Trigger

Corcept Therapeutics (NASDAQ: CORT) is a commercial-stage biotech focused on drugs that modulate the hormone cortisol for treating severe endocrine disorders (ir.corcept.com). Its flagship product Korlym (mifepristone) has been marketed since 2012 for hypercortisolism (Cushing’s syndrome) (www.sec.gov). Corcept has been developing a next-generation therapy relacorilant for the same indication, aiming to avoid Korlym’s off-target effects. On December 31, 2025, the FDA issued a Complete Response Letter (CRL) declining to approve relacorilant’s New Drug Application for hypercortisolism, citing the need for additional evidence of effectiveness (intellectia.ai). This effectively rejected the relacorilant NDA (targeted at treating hypertension secondary to Cushing’s) and caused Corcept’s stock to plunge from $70.20 to $34.80 – a one-day collapse of 50.4% in share value (intellectia.ai). The FDA’s response acknowledged data from Corcept’s GRACE trial but concluded efficacy evidence was insufficient for approval.

This unexpected FDA rejection has now spurred a wave of shareholder litigation. Within weeks, multiple law firms announced securities class action lawsuits alleging that Corcept misled investors about relacorilant’s approval prospects (intellectia.ai). According to the complaints, Corcept touted “powerful support” from its clinical trials and suggested its lead product was nearing approval, despite receiving multiple FDA warnings about inadequate clinical data well before the NDA decision (intellectia.ai) (intellectia.ai). In other words, the company is accused of concealing regulatory risks – painting an overly optimistic picture of relacorilant’s outlook even as the FDA had raised serious concerns. The class period spans October 31, 2024 through December 30, 2025 (the day before the CRL), implying that investors who bought during this time may have been influenced by the alleged misstatements (www.prnewswire.com). The stock’s violent drop on the CRL news crystallized heavy losses, and law firms are seeking lead plaintiffs to pursue damages (www.prnewswire.com) (intellectia.ai). The core allegation is that Corcept’s management failed to disclose the FDA’s feedback and the true approval risk, thereby violating securities laws once the truth came to light. This legal overhang raises serious governance red flags and could entail costly settlements or judgements down the line.

Dividend Policy and Shareholder Returns

Corcept does not pay any dividend and has never declared one in its corporate history (www.sec.gov) (www.sec.gov). Management has consistently retained earnings to reinvest in R&D and commercialization rather than returning cash via dividends – a common practice for growth-focused biotech companies. The company explicitly states it does not anticipate paying cash dividends in the foreseeable future (www.sec.gov). However, Corcept has employed share repurchases as an alternative way to return capital to shareholders. For example, in early 2025 the company bought back roughly $27.4 million of its stock (as part of a $39.8 million cash outflow in Q1 2025 financing activities) (www.panabee.com). This indicates a willingness to use excess cash for buybacks, potentially to offset dilution from equity awards or signal confidence. Given the lack of dividend yield, share buybacks have been the primary means of shareholder return – albeit at a modest scale relative to Corcept’s market capitalization. Going forward, any continuation of repurchases will likely depend on the company’s cash needs for pipeline development and legal contingencies.

Leverage, Liquidity and Coverage

Corcept’s balance sheet remains debt-free, reflecting a conservative capital structure. The company carries no long-term debt or outstanding loans, thereby incurring no interest expense and facing no near-term debt maturities. Instead, Corcept is sitting on a substantial cash war chest. As of year-end 2025, it held $120.5 million in cash and $411.9 million in marketable securities (primarily short-term and investment-grade instruments) (www.sec.gov) (www.sec.gov). This totals to over $532 million in liquid assets, providing a significant cushion for operations and strategic initiatives. With total liabilities of only ~$189 million consisting mostly of payables and accrued expenses (www.sec.gov), Corcept’s net cash position exceeds $340 million. In 2025 the company even earned $21.7 million in interest and other income thanks to its invested cash, which helped boost pre-tax income (www.sec.gov).

This fortress-like liquidity means leverage is not a concern – Corcept can fund its R&D pipeline and legal battles without needing debt financing in the near term. Key coverage ratios are extremely healthy given the absence of interest-bearing debt (interest coverage is essentially infinite, as there are no interest obligations to cover). The company’s operating cash flow remains positive (albeit pressured by rising expenses), and its ample cash ensures high financial flexibility. In sum, Corcept’s liquidity profile is strong: it has the resources to absorb setbacks like the relacorilant delay and to potentially weather adverse events (such as a revenue drop or lawsuit costs) without immediate solvency risk. This conservative balance sheet is a critical buffer given the volatile outlook.

Recent Performance and Valuation

Despite the regulatory setback, Corcept’s underlying business has been profitable and growing, though margins are tightening. The company’s sole commercial product Korlym has driven robust top-line expansion. 2025 revenue reached $761.4 million, up +13% from $675.0 million in 2024 (www.sec.gov). This growth was fueled by increased prescriptions for hypercortisolism and possibly pricing, even as generic competition loomed (Corcept launched its own authorized generic of Korlym in mid-2024) (www.sec.gov). However, expenses have ramped up dramatically. In 2025, R&D and SG&A costs surged as Corcept invested in expanding its commercial infrastructure and advancing relacorilant and other pipeline programs (www.sec.gov). Notably, Selling, General & Administrative expense jumped to $448.7 million in 2025 from $280.3 million in 2024 (www.sec.gov), reflecting heavy marketing spend (likely in anticipation of relacorilant’s launch and to fend off generics). This squeezed operating income to just $44.8 million in 2025, down from $137.0 million the prior year (www.sec.gov). Corcept’s net income consequently fell 30% to $99.7 million in 2025 (versus $141.2M in 2024) (www.sec.gov), despite a one-time tax benefit that year.

In terms of valuation, Corcept’s stock now trades well off its 2025 highs, yet still at rich earnings multiples. After the FDA rejection-triggered plunge, CORT shares stabilized in the mid-$30s to $40 range in early 2026. Based on trailing fundamentals, this equates to a price-to-earnings ratio around 45–50 (TTM P/E ≈47 as of February 2026) (www.macrotrends.net). Even with the stock nearly halved from its peak, the market is pricing in a premium valuation – likely reflecting optimism for Corcept’s pipeline and intellectual property. On a price-to-sales basis, the stock trades near ~4.5× 2025 revenue, and its enterprise value is about 4.4× sales when accounting for net cash. These multiples are elevated relative to broad market averages, underscoring that investors were (and perhaps still are) embedding significant growth and pipeline success in Corcept’s valuation. However, with relacorilant’s approval delayed and generic Korlym looming, such a valuation may be increasingly hard to justify. If earnings deteriorate or growth stalls, current multiples could compress. Corcept’s forward valuation will hinge on how it navigates the upcoming challenges – a point of uncertainty given recent events. For now, the stock’s pricing suggests cautious optimism tempered by newly heightened risk.

Risks, Red Flags and Open Questions

Corcept faces multiple critical risks and red flags following the FDA’s rejection and subsequent legal fallout:

– Pipeline Reliance & Regulatory Risk: The relacorilant CRL in Dec 2025 raises serious questions about Corcept’s growth trajectory. Relacorilant was the company’s most important pipeline candidate – intended as a safer, next-generation Cushing’s drug to eventually replace or supplement Korlym. With the FDA now demanding additional efficacy evidence, relacorilant’s approval is delayed indefinitely, pending new trials or data. This not only defers any revenue boost but also casts doubt on management’s regulatory strategy. Why were the FDA’s concerns not resolved pre-submission? How quickly (if at all) can Corcept satisfy the FDA’s requirements to salvage relacorilant? These open questions will overhang the stock. Management has yet to clearly outline a path forward post-CRL, leaving investors uncertain if relacorilant’s issues are fixable in the near term.

– Securities Litigation & Governance: The emerging class action lawsuits are a red flag regarding corporate transparency and governance. Plaintiffs allege Corcept misled investors about relacorilant’s prospects, implying potential failures in disclosure or even possible management over-optimism verging on fraud (intellectia.ai). While such shareholder suits are not uncommon after biotech setbacks, the accusations here are specific: that Corcept knew of FDA feedback (or lack of “adequate clinical evidence”) but publicly remained bullish. If evidence supports these claims, it suggests poor judgment by management in communications and could erode investor trust. At minimum, Corcept will incur legal expenses (though D&O insurance may defray some costs), and a settlement or adverse ruling could be material. The situation raises a governance question: will there be any accountability or changes in management if the market concludes they were not forthcoming about risks?

– Concentration Risk – Korlym Dependency: Corcept’s entire current revenue ($761M in 2025) comes from Korlym (mifepristone) sales for hypercortisolism (www.sec.gov). This single-product dependence is now a glaring vulnerability. Generic competition is a near-term existential threat to Korlym’s franchise. Notably, Teva Pharmaceuticals launched a generic Korlym in early 2024, following a legal battle where Corcept’s patents were challenged (www.sec.gov). Corcept attempted to defend its intellectual property, but a federal court found Teva’s generic does not infringe the two key patents Corcept asserted (fintool.com). In February 2026, the U.S. Court of Appeals upheld that ruling, removing the last major legal barrier to full generic competition (fintool.com) (fintool.com). This outcome ended an 8-year patent fight that Corcept had hoped would protect Korlym exclusivity until 2037 (fintool.com). As a result, Corcept’s stock plunged ~25% on the news of the appellate loss (fintool.com). The company has said it is “disappointed” and is considering further review, but the reality is that multiple generics may now enter the market imminently. (Corcept already preemptively launched its own authorized generic in mid-2024 to retain some market share (www.sec.gov), and it has settlement deals with other generics like Sun and Hikma for future entry (www.sec.gov).) The open question is how severely Korlym sales will erode and how quickly. A sudden revenue decline is likely as payers and physicians switch to far cheaper generic mifepristone. Corcept itself warns that generic Korlym availability could materially harm its results and cause revenues to fall below guidance (www.sec.gov) (www.sec.gov). Investors must monitor how Korlym volumes and pricing hold up in 2026 and whether Corcept can offset any loss (e.g. via its own generic or new indications). The viability of Corcept’s business model is at stake, since Korlym funds all its R&D a collapse in Korlym revenue would force major cost cuts or cash burn, potentially leading to a need for external financing despite the current cash reserves.

– Expense Growth & Profitability Pressure: Another risk is Corcept’s ballooning cost structure. The company’s operating expenses (especially SG&A) have risen dramatically – in part to support anticipated new product launches and to expand the salesforce. Now that relacorilant is delayed and Korlym’s future sales might shrink, Corcept may be left overscaled. If revenues decline (or grow slower) while expenses remain high, profit margins could vanish. Already in 2025, Corcept’s operating margin fell to under 6% (from 20%+ a year prior) due to expense growth far outpacing revenue (www.sec.gov) (www.sec.gov). Without swift cost realignment, the company could even see net losses in a generic-competition scenario. Management’s ability (and willingness) to pivot the cost base in response to changing fundamentals is an open question. Will they scale back commercial spend now that relacorilant’s approval is postponed? Can R&D be prioritized more efficiently? The risk is that Corcept’s current expense trajectory is unsustainable if top-line growth falters.

– Patent Cliff and Competition: Beyond Teva, other competitors are on the horizon. Corcept’s patent estate for Korlym consists of method-of-use patents extending to 2028–2038, but these are now proven vulnerable (www.sec.gov) (www.sec.gov). The company has indicated it will “vigorously protect” its IP, yet the loss against Teva signals that at least some claims won’t hold. Settlements with generic makers Sun and Hikma allow them to launch as early as 2034 (per Corcept’s legal disclosures) (www.sec.gov) – or sooner if certain conditions are met. Additionally, new medical therapies for Cushing’s could emerge. For instance, Recordati markets a competing treatment (pasireotide) and other novel agents or off-label uses could capture patient share (www.sec.gov). All these competitive forces compound the uncertainty around Corcept’s future revenue stream.

– Open Questions – Strategy and Pipeline: With Korlym’s moat crumbling and relacorilant stalled, what is Corcept’s strategy to rebuild value? The company does have other pipeline programs (including relacorilant in oncology trials and selective cortisol modulators for different indications). In fact, a separate NDA for relacorilant in platinum-resistant ovarian cancer is under FDA review with a PDUFA action date of July 11, 2026 (ir.corcept.com) (ir.corcept.com). Success in that oncology indication could provide a new revenue source. However, the CRL in Cushing’s might hint at broader regulatory skepticism, and it remains to be seen if relacorilant can demonstrate clear benefit in cancer. Investors are also questioning if Corcept can leverage its cash (over $500M) for strategic moves – e.g. in-licensing new candidates or even exploring a sale/merger now that its valuation is lower. Another open question is how management navigates the next 12–18 months: Can they regain FDA’s favor on relacorilant? Will they adjust the cost structure and preserve cash? How will they deploy the authorized generic strategy to defend market share? The answers to these will determine whether Corcept’s story stabilizes or further unravels.

Overall, Corcept Therapeutics is at a pivotal juncture. The recent FDA rejection and class action allegations have undermined confidence, while the looming generic competition to its sole product threatens its financial foundation. The company’s strong balance sheet and past profitability provide some resilience, but major strategic and execution risks lie ahead. Investors will be watching for concrete plans from management to address the regulatory setbacks and to diversify beyond Korlym. Until then, significant uncertainty persists around CORT’s valuation and trajectory. The risk profile has clearly risen, and the stock’s future performance will hinge on management’s response to these interlocking challenges.

Sources: Corcept 10-K 2025 & SEC filings (www.sec.gov) (www.sec.gov); Corcept IR news (intellectia.ai) (www.sec.gov); PRNewswire/Law firm releases (intellectia.ai); Fintel/Fintool news on patent litigation (fintool.com); Drugs.com & company disclosures on Korlym generics (www.drugs.com) (www.sec.gov).

For informational purposes only; not investment advice.